<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6. Effect of Other Drugs on Voriconazole Pharmacokinetics [see Clinical Pharmacology (<linkhtml href="#i4i_pharmacokinetics_id_f68ea8ed-01b6-4934-8c9d-934aa9e6531a">12.3</linkhtml>)]</caption>
<col width="33%"></col>
<col width="33%"></col>
<col width="33%"></col>
<tbody>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drug/Drug Class</content>
</paragraph>
<paragraph>
<content stylecode="bold">(Mechanism of Interaction by the Drug)</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Voriconazole Plasma Exposure</content>
</paragraph>
<paragraph>
<content stylecode="bold">(C<sub>max</sub> and AUC</content>
<sub>τ</sub>
<content stylecode="bold">after 200 mg q12h)</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Recommendations for Voriconazole</content>
</paragraph>
<paragraph>
<content stylecode="bold">Dosage Adjustment/Comments</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Rifampin<footnote id="_Refid-ec3dd60b-7176-4473-bd38-485645f2c">Results based on <content stylecode="italics">in vivo </content>clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects</footnote> and Rifabutin <footnoteref idref="_Refid-ec3dd60b-7176-4473-bd38-485645f2c"></footnoteref>
</paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Efavirenz (400 mg q24h)<footnote id="_Refid-06701971-f9a7-4957-9544-3d607936f">Results based on <content stylecode="italics">in vivo </content>clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects</footnote>
</paragraph>
<paragraph>(CYP450 Induction) <br/> <br/>Efavirenz (300 mg q24h)<footnoteref idref="_Refid-06701971-f9a7-4957-9544-3d607936f"></footnoteref>
<br/>(CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Significantly Reduced <br/> <br/>Slight Decrease in AUC<sub>τ</sub>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated</content>
<br/>
<content stylecode="bold"> </content>
<br/>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule " valign="top">
<paragraph>High dose Ritonavir (400 mg q12h)<footnoteref idref="_Refid-06701971-f9a7-4957-9544-3d607936f"></footnoteref>
</paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Low dose Ritonavir (100 mg q12h)<footnoteref idref="_Refid-06701971-f9a7-4957-9544-3d607936f"></footnoteref>
</paragraph>
<paragraph>(CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Reduced</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Coadministration of voriconazole and low dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Carbamazepine </paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Long-acting Barbiturates </paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Phenytoin<footnoteref idref="_Refid-ec3dd60b-7176-4473-bd38-485645f2c"></footnoteref>
</paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>St. John’s Wort </paragraph>
<paragraph>(CYP450 inducer; P-gp inducer) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Oral Contraceptives<footnoteref idref="_Refid-06701971-f9a7-4957-9544-3d607936f"></footnoteref>
</paragraph>
<paragraph>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Increased </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Fluconazole<footnoteref idref="_Refid-06701971-f9a7-4957-9544-3d607936f"></footnoteref>
<br/> (CYP2C9, CYP2C19 and CYP3A4 Inhibition)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Significantly Increased</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole.</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Other HIV Protease Inhibitors </paragraph>
<paragraph>(CYP3A4 Inhibition) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">In Vivo </content>Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism</paragraph>
<paragraph>(Increased Plasma Exposure)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="middle">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Other NNRTIs<footnote id="_Refid-00299129-c1cd-4014-8593-30d979364">Non-Nucleoside Reverse Transcriptase Inhibitors</footnote>
</paragraph>
<paragraph>(CYP3A4 Inhibition or CYP450 </paragraph>
<paragraph>Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule " valign="top">
<paragraph>
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure) </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule " valign="top">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure)</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Careful assessment of voriconazole effectiveness</paragraph>
</td>
</tr>
</tbody>
</table>